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Background:  CXL-1020 is a novel HNO donor that, in vivo, chemically converts rapidly to HNO and an organic byproduct. CXL-1020 produces 
load-independent positive inotropy and lusitropy in the failing left ventricle, while simultaneously decreasing cardiac loading conditions in various 
heart failure animal models.
Objectives:To demonstrate the safety and tolerability of intravenous CXL-1020 in stable chronic congestive heart failure patients without significant 
volume overload, and to assess pharmacokinetics (PK) in plasma and urine.
Methods:  Cohorts 1 and 2 (n=13 patients and 52 doses, 62±9 years; 11/13 males; mean left ventricular ejection fraction 32± 11%) were 
evaluated in a dose ranging, double-blind, randomized, and placebo-controlled study involving 4 sequentially increasing 4-hour infusions, at half-log 
dose increments between 0.1-30 ug/kg/min with a randomly interspersed placebo. Electrophysiological safety was evaluated with 12 lead digital 
Holter and HR and arterial blood pressure was monitored throughout the study. Plasma and urine PK samples were obtained during treatment and 
up to 24 hrs post dosing. All evaluations were done in the presence of background medication.
Results: CXL-1020 was well tolerated at doses up to 10 ug/kg/min with no significant change in heart rate or systolic blood pressure (SBP), 
and no increase in ventricular ectopy. At the highest dose of 30 ug/kg/min, 33% of patients (2 of 6) met a pre-specified criterion for termination 
of treatment due to a fall of systolic blood pressure of >20 mmHg. Upon termination of treatment blood pressure returned rapidly to baseline. No 
drug related SAEs were observed, nor was there evidence of any arrhythmogenicity. No decrement in renal function was observed. Dose-proportional 
plasma PK was observed for both CXL-1020 and its byproduct; ~90% of the by-product was recovered unchanged in the urine. 
Conclusions:  This “first in man” study suggests that CXL-1020 is safe and well tolerated in patients with congestive heart failure, and 
demonstrates dose proportional and predictable PK. Additional clinical studies are underway to define safety, tolerability and utility of CXL-1020 in 
decompensated heart failure pateints.
